Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

1.4K
This article demonstrates a Chinese herbal retention enema method for treating ulcerative colitis, which can effectively improve patients' clinical symptoms and quality of...
1.4K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

908
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
908
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

466
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
466
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

10.5K
Systematic scoring of intestinal inflammation using a free computer-assisted system is a powerful tool to quantitatively compare histopathological changes in colitis models characterized by the presence of ulcers and inflammatory changes. Histological colitis score evaluation strengthens clinical observations and facilitates data...
10.5K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

12.8K
Current treatments of inflammatory bowel diseases (IBD) aim at alleviating disease symptoms but may cause severe side effects. Thus, alternative strategies are being investigated in animal colitis models. Here, we explain how the beneficial effects of diet supplements on clinical IBD signs are analyzed in such a colitis...
12.8K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

32.5K
Over the past few years, new generation endoscopes have emerged as important diagnostic research aids for evaluating murine colitis and colorectal tumors. We present herein a detailed protocol for endoscopic assessment of inflammation and colorectal tumors in mice, as well as a novel scoring system that uses decimal identifiers to document the endoscopic severity of colitis and colorectal...
32.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cholinergic modulation of hippocampal CA1 pyramidal cell excitability in Arx<sup>GCG+7</sup> mice.

Experimental neurology·2025
Same author

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

bioRxiv : the preprint server for biology·2025
Same author

Prevalence of Esophageal Webs in Patients Undergoing Direct Laryngoscopy.

The Laryngoscope·2025
Same author

Venolaryngeal Obstruction Syndrome (VLOS): Characterizing Airway Obstruction in Massive Thyroid Goiters.

The Annals of otology, rhinology, and laryngology·2025
Same author

Close outpatient follow-up associated with reduced readmission rates in patients with inflammatory bowel disease.

Proceedings (Baylor University. Medical Center)·2024
Same author

Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.

European journal of gastroenterology & hepatology·2024
Same journal

Management of Common Bile Duct Stones: Current Approaches and Evolving Endoscopic Strategies.

Current gastroenterology reports·2026
Same journal

Solitary Rectal Ulcer Syndrome Revisited: A Comprehensive Narrative Review.

Current gastroenterology reports·2026
Same journal

The Microbiome and Esophageal Disease: Where Are We Now?

Current gastroenterology reports·2026
Same journal

Fermented Durian Tempoyak as a Source of Probiotics for Colorectal Cancer Prevention through Gut Microbiome Modulation.

Current gastroenterology reports·2026
Same journal

A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.

Current gastroenterology reports·2026
Same journal

The Role of Endoscopic Ultrasound in the Diagnosis and Management of Congenital Gastrointestinal and Pancreaticobiliary Conditions.

Current gastroenterology reports·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.4K

Maneuvering Clinical Pathways for Ulcerative Colitis.

Christopher M Johnson1, Catherine D Linzay2, Themistocles Dassopoulos3,4

  • 1Baylor Scott and White Medical Center, Baylor Scott and White Health, Temple, TX, USA.

Current Gastroenterology Reports
|September 6, 2019
PubMed
Summary
This summary is machine-generated.

New ulcerative colitis (UC) treatments, including vedolizumab and tofacitinib, are expanding therapeutic options. Risk-stratified and treat-to-target approaches offer personalized management strategies for UC patients.

Keywords:
Inflammatory bowel diseaseTofacitinibUlcerative colitisVedolizumab

More Related Videos

Inflammatory Bowel Disease I: Ulcerative Colitis
01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

908
Drugs for Treatment of Ulcerative Colitis in IBD
01:29

Drugs for Treatment of Ulcerative Colitis in IBD

466

Related Experiment Videos

Last Updated: Jan 20, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.4K
Inflammatory Bowel Disease I: Ulcerative Colitis
01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

908
Drugs for Treatment of Ulcerative Colitis in IBD
01:29

Drugs for Treatment of Ulcerative Colitis in IBD

466

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Recent advancements have expanded treatment options for ulcerative colitis (UC).
  • Established therapies and newer agents like vedolizumab and tofacitinib are available.
  • Current management paradigms are evolving with novel therapeutic strategies.

Purpose of the Study:

  • To review salient recommendations from recent ulcerative colitis treatment guidelines.
  • To evaluate the efficacy, safety, and real-world data of vedolizumab and tofacitinib.
  • To consider emerging approaches such as risk-stratified and treat-to-target therapy in UC management.

Main Methods:

  • Review of recent treatment guidelines for ulcerative colitis.
  • Analysis of published efficacy, safety, and real-world data for vedolizumab and tofacitinib.
  • Appraisal of the role of new agents in comparison to established treatments.

Main Results:

  • Once-daily oral mesalamine is as effective as split dosing for mild-moderate UC.
  • Real-world data support vedolizumab's effectiveness and safety in moderate-to-severe UC; limited data exist for tofacitinib.
  • New approaches like risk-stratified and treat-to-target therapy are shifting UC management paradigms.

Conclusions:

  • Therapeutic options for ulcerative colitis are continuously expanding.
  • Risk-stratified and treat-to-target approaches represent significant shifts in UC management.
  • Optimal UC control necessitates an individualized approach considering inflammation, long-term risk, patient preferences, and treatment response.